Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $11.0 million.

  • Rhythm Pharmaceuticals' Change in Accured Expenses rose 4671.02% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 20883.85%. This contributed to the annual value of $21.9 million for FY2024, which is 4836.53% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $11.0 million for Q3 2025, which was up 4671.02% from $13.3 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $15.7 million during Q4 2022, with a 5-year trough of -$12.6 million in Q3 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was $4.9 million (2023), whereas its average is $4.1 million.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Change in Accured Expenses plummeted by 30983.31% in 2022 and then soared by 984905.66% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $12.9 million in 2021, then rose by 21.61% to $15.7 million in 2022, then plummeted by 69.08% to $4.9 million in 2023, then skyrocketed by 212.45% to $15.2 million in 2024, then fell by 27.43% to $11.0 million in 2025.
  • Its last three reported values are $11.0 million in Q3 2025, $13.3 million for Q2 2025, and -$3.6 million during Q1 2025.